Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

Peripheral T cell cytotoxicity predicts T cell function in the tumor microenvironment.

Iwahori K, Shintani Y, Funaki S, Yamamoto Y, Matsumoto M, Yoshida T, Morimoto-Okazawa A, Kawashima A, Sato E, Gottschalk S, Okumura M, Kumanogoh A, Wada H.

Sci Rep. 2019 Feb 22;9(1):2636. doi: 10.1038/s41598-019-39345-5.

2.

Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.

Ascierto PA, Agarwala S, Botti G, Cesano A, Ciliberto G, Davies MA, Demaria S, Dummer R, Eggermont AM, Ferrone S, Fu YX, Gajewski TF, Garbe C, Huber V, Khleif S, Krauthammer M, Lo RS, Masucci G, Palmieri G, Postow M, Puzanov I, Silk A, Spranger S, Stroncek DF, Tarhini A, Taube JM, Testori A, Wang E, Wargo JA, Yee C, Zarour H, Zitvogel L, Fox BA, Mozzillo N, Marincola FM, Thurin M.

J Transl Med. 2016 Nov 15;14(1):313.

3.

Circulating T Cell Subpopulations Correlate With Immune Responses at the Tumor Site and Clinical Response to PD1 Inhibition in Non-Small Cell Lung Cancer.

Manjarrez-Orduño N, Menard LC, Kansal S, Fischer P, Kakrecha B, Jiang C, Cunningham M, Greenawalt D, Patel V, Yang M, Golhar R, Carman JA, Lezhnin S, Dai H, Kayne PS, Suchard SJ, Bernstein SH, Nadler SG.

Front Immunol. 2018 Aug 3;9:1613. doi: 10.3389/fimmu.2018.01613. eCollection 2018.

4.

Harnessing the Immune System Against Leukemia: Monoclonal Antibodies and Checkpoint Strategies for AML.

Masarova L, Kantarjian H, Garcia-Mannero G, Ravandi F, Sharma P, Daver N.

Adv Exp Med Biol. 2017;995:73-95. doi: 10.1007/978-3-319-53156-4_4. Review.

PMID:
28321813
5.

A high density of tertiary lymphoid structure B cells in lung tumors is associated with increased CD4+ T cell receptor repertoire clonality.

Zhu W, Germain C, Liu Z, Sebastian Y, Devi P, Knockaert S, Brohawn P, Lehmann K, Damotte D, Validire P, Yao Y, Valge-Archer V, Hammond SA, Dieu-Nosjean MC, Higgs BW.

Oncoimmunology. 2015 Jun 1;4(12):e1051922. eCollection 2015 Dec.

6.

Precision medicine in immune checkpoint blockade therapy for non-small cell lung cancer.

Liu X, Cho WC.

Clin Transl Med. 2017 Dec;6(1):7. doi: 10.1186/s40169-017-0136-7. Epub 2017 Jan 20.

7.

Resistance to anti-PD-1-based immunotherapy in basal cell carcinoma: a case report and review of the literature.

Sabbatino F, Marra A, Liguori L, Scognamiglio G, Fusciello C, Botti G, Ferrone S, Pepe S.

J Immunother Cancer. 2018 Nov 20;6(1):126. doi: 10.1186/s40425-018-0439-2.

8.

Immune therapies in acute myeloid leukemia: a focus on monoclonal antibodies and immune checkpoint inhibitors.

Assi R, Kantarjian H, Ravandi F, Daver N.

Curr Opin Hematol. 2018 Mar;25(2):136-145. doi: 10.1097/MOH.0000000000000401. Review.

PMID:
29206680
9.

Deconvolution of the gene expression profiles of valuable banked blood specimens for studying the prognostic values of altered peripheral immune cell proportions in cancer patients.

Qi L, Li B, Dong Y, Xu H, Chen L, Wang H, Li P, Zhao W, Gu Y, Wang C, Guo Z.

PLoS One. 2014 Jun 24;9(6):e100934. doi: 10.1371/journal.pone.0100934. eCollection 2014.

10.

Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.

Herzberg B, Campo MJ, Gainor JF.

Oncologist. 2017 Jan;22(1):81-88. doi: 10.1634/theoncologist.2016-0189. Epub 2016 Aug 17. Review.

11.

Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy.

La-Beck NM, Jean GW, Huynh C, Alzghari SK, Lowe DB.

Pharmacotherapy. 2015 Oct;35(10):963-76. doi: 10.1002/phar.1643. Review. Erratum in: Pharmacotherapy. 2015 Dec;35(12):1205.

PMID:
26497482
12.

Prospects for personalized combination immunotherapy for solid tumors based on adoptive cell therapies and immune checkpoint blockade therapies.

Kato D, Yaguchi T, Iwata T, Morii K, Nakagawa T, Nishimura R, Kawakami Y.

Nihon Rinsho Meneki Gakkai Kaishi. 2017;40(1):68-77. doi: 10.2177/jsci.40.68. Review.

13.

Development of immune checkpoint inhibitors.

Kitano S.

Rinsho Ketsueki. 2017;58(8):966-976. doi: 10.11406/rinketsu.58.966. Japanese.

PMID:
28883282
14.

Novel immunotherapy in the treatment of advanced non-small cell lung cancer.

Santabarbara G, Maione P, Rossi A, Palazzolo G, Gridelli C.

Expert Rev Clin Pharmacol. 2016 Dec;9(12):1571-1581. Epub 2016 Sep 23. Review.

PMID:
27623999
15.

Immune checkpoint blockade as a potential therapeutic target in non-small cell lung cancer.

Yang J, Chen J, Wei J, Liu X, Cho WC.

Expert Opin Biol Ther. 2016 Oct;16(10):1209-23. doi: 10.1080/14712598.2016.1214265. Epub 2016 Aug 5. Review.

PMID:
27426430
16.

Cancer Immunotherapy Targets Based on Understanding the T Cell-Inflamed Versus Non-T Cell-Inflamed Tumor Microenvironment.

Gajewski TF, Corrales L, Williams J, Horton B, Sivan A, Spranger S.

Adv Exp Med Biol. 2017;1036:19-31. doi: 10.1007/978-3-319-67577-0_2. Review.

PMID:
29275462
17.

PD-L1 on peripheral blood T lymphocytes is prognostic in patients with non-small cell lung cancer (NSCLC) treated with EGFR inhibitors.

Meniawy TM, Lake RA, McDonnell AM, Millward MJ, Nowak AK.

Lung Cancer. 2016 Mar;93:9-16. doi: 10.1016/j.lungcan.2015.12.006. Epub 2015 Dec 30.

PMID:
26898608
18.

Characterization of the T cell repertoire by deep T cell receptor sequencing in tissues and blood from patients with advanced colorectal cancer.

Tamura K, Hazama S, Yamaguchi R, Imoto S, Takenouchi H, Inoue Y, Kanekiyo S, Shindo Y, Miyano S, Nakamura Y, Kiyotani K.

Oncol Lett. 2016 Jun;11(6):3643-3649. Epub 2016 Apr 19.

19.

The Emerging Role of CD8+ Tissue Resident Memory T (TRM) Cells in Antitumor Immunity: A Unique Functional Contribution of the CD103 Integrin.

Corgnac S, Boutet M, Kfoury M, Naltet C, Mami-Chouaib F.

Front Immunol. 2018 Aug 15;9:1904. doi: 10.3389/fimmu.2018.01904. eCollection 2018. Review.

20.

Characteristics and prognostic significance of profiling the peripheral blood T-cell receptor repertoire in patients with advanced lung cancer.

Liu YY, Yang QF, Yang JS, Cao RB, Liang JY, Liu YT, Zeng YL, Chen S, Xia XF, Zhang K, Liu L.

Int J Cancer. 2019 Jan 21. doi: 10.1002/ijc.32145. [Epub ahead of print]

PMID:
30664810

Supplemental Content

Support Center